Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Enablex Given Green Light for Clinical Trials By China’s SFDA

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA has officially accepted BMP Sunstone's clinical trial application for Novartis' Enablex (darifenacin), the company announced May 6.

You may also be interested in...



Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition

Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys

Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition

Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys

Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 2 of 2)

[Editor's Note: This is part two of a two-part interview. Part one appeared May 4, 2008 in PharmAsia News.]

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel